NCT07191535View on ClinicalTrials.gov

Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

January 1, 2027

Study Completion Date

September 1, 2027

Conditions
Asthma (Diagnosis)Pulmonary FunctionModerate-to-Severe Asthma
Interventions
DRUG

linvemastat

Matrix Metalloproteinase-12 inhibitor

DRUG

Placebo

Placebo

Sponsors
All Listed Sponsors
collaborator

QPS Holdings LLC

INDUSTRY

lead

Foresee Pharmaceuticals Co., Ltd.

INDUSTRY